The SWITCH Study is an antiretroviral drug switch
intervention for fat atrophy.
Purpose: |
This research study seeks to determine if
replacing Zerit in an effective antiretroviral regimen with
Viread (Tenofovir) as prescribed by your physician, will have
a beneficial impact on fat atrophy (loss of fat) and maintain
viral suppression. |
Eligibility
Criteria: |
- HIV +
- On d4T for at least 6 months
- Have facial fat atrophy
- Over 18 years
|
Study
Requirements: |
Study visits will be monthly for the first
three months, then every three months for the remainder of this
research study. There will be a total of seven study visits.
|
Benefits: |
Receive detailed information about your body
composition through DXA and CT scans.
|
Study
Personnel: |
| Christine Wanke,
MD |
Principal Investigator |
|
Contact: |
Call 617-636-
0921
Privacy and confidentiality are strictly maintained.
TOP
|
